TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	USD 1.630	-5.78%	16,185
29/10/26	USD 1.730	-0.57%	40,837
28/10/26	USD 1.740	+4.19%	18,494
27/10/26	USD 1.670	-2.08%	7,503
26/10/26	USD 1.706	-3.64%	54,291

Delayed Quote Nasdaq

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - TransCode Therapeutics, Inc.

Company calendar

Market Closed - Nasdaq 07:00:00 31/10/26 am AEDT			5-day change	1st Jan Change
1.630 ^USD	-5.78%		-7.91%	-76.13%

30/10	TransCode Therapeutics, Inc. Engages Tungsten Advisors to Consider Strategic Options	CI
19/10	Transcode Therapeutics, Inc. Presents Phase 1A Clinical Trial Data for Ttx-Mc138 At Esmo Congress 2026	CI

Market Cap	27.6M 24.72M 22.73M 20.6M 38.51M 2.62B 39.23M 271M 109M 1.38B 104M 101M 4.35B	P/E 2024	-0.07x	P/E 2025	-0.13x
Enterprise Value	9.78M 8.76M 8.06M 7.3M 13.65M 929M 13.91M 96.11M 38.58M 489M 36.72M 35.94M 1.54B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	98.22%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	RNAZ	Delayed
CBOE	RNAZ	Real-time

30/10	TransCode Therapeutics, Inc. Engages Tungsten Advisors to Consider Strategic Options	CI
19/10	Transcode Therapeutics, Inc. Presents Phase 1A Clinical Trial Data for Ttx-Mc138 At Esmo Congress 2026	CI
14/10	Natera, Inc. and TransCode Therapeutics, Inc. Collaborate on Phase 2A Trial of TTX-MC138 in Colorectal Cancer	CI
13/10	Natera, TransCode Collaborate to Improve Enrollment for Colorectal Cancer Trial	MT
28/09	TransCode Therapeutics, Inc. Reports Updated Clinical Data from Its Phase 1A Clinical Trial of TTX-MC138	CI
23/09	TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology	CI
17/09	TransCode Therapeutics, Inc. - Special Call
11/09	Transcode Therapeutics, Inc. Announces CFO Changes, Effective September 9, 2026	CI
11/09	Transcode Therapeutics, Inc. Announces Management Changes, Effective from September 9, 2026	CI
01/09	TransCode Therapeutics, Inc Announces Publication Demonstrating Survival Benefit Of TTX-MC138 In Preclinical Model Of Breast Cancer Bone Metastasis	CI
15/08	TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
19/06	TransCode Therapeutics, Inc. - Special Call
03/06	TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a	MT

TransCode Therapeutics, Inc. Stock

Stocks

RNAZ

US89357L5012

Biotechnology & Medical Research

Valuation: TransCode Therapeutics, Inc.

Chart: TransCode Therapeutics, Inc.

Latest news: TransCode Therapeutics, Inc.

Last Transcript: TransCode Therapeutics, Inc.

Analysts' recommendations: TransCode Therapeutics, Inc.

Press Releases: TransCode Therapeutics, Inc.

News in other languages: TransCode Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: TransCode Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

14/10/25	Transcode Therapeutics completes phase 1a trial with TTX-MC138 in metastatic disease at ESMO - SEC filing	RE
16/11/22	HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating	MT
07/06/22	HC Wainwright Starts TransCode Therapeutics at Buy With $10 Price Target	MT

16/09	Join Today's Live Investor Webinar with TransCode Therapeutics	AQ
03/09	Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer	AQ
07/08	Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV	AQ
04/03	TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients	PR
24/02	TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development	PR

1 day	-5.78%
1 week	-7.91%
Current month	-2.98%
1 month	-2.98%
3 months	-68.95%
6 months	-79.65%
Current year	-76.13%

1 week	1.61	1.91
1 month	1.54	1.95
Current year	1.52	12.6
1 year	1.52	12.6
3 years	1.52	17,947.76
5 years	1.52	2,557,658.19
10 years	1.52	5,174,452.99

Manager	Title	Age	Since
Philippe Calais CEO	Chief Executive Officer	67	06/10/2025
Zdravka Medarova CTO	Chief Tech/Sci/R&D Officer	52	01/10/2021
John Tattory DFI	Director of Finance/CFO	61	10/09/2026

Director	Title	Age	Since
Philippe Calais CHM	Chairman	67	18/02/2021
Erik Manting BRD	Director/Board Member	54	20/12/2020
Magda Marquet BRD	Director/Board Member	67	01/01/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/9/26	Thomas Fitzgerald	Free	Chief Executive Officer	185,000	1.0927%
3/8/26	CK LIFE SCIENCES INTERNATIONAL (HOLDINGS), INC.	Conversion	Company	13,834,441	81.7120%
27/7/26	CK LIFE SCIENCES INTERNATIONAL (HOLDINGS), INC.	Other	Company	300,040	1.7722%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSCODE THERAPEUTICS, INC.	-5.78%	-7.91%	-85.11%	-99.99%	27.6M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	41B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-42.03%	+373.03%	24.7B
Average	-0.27%	+5.99%	+34.56%	+175.69%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+48.49%	+186.11%

	2024	2025
Net sales	-	-
Net income	-16.75M -15.01M -13.8M -12.51M -23.38M -1.59B -23.82M -165M -66.08M -837M -62.88M -61.54M -2.64B	-34.66M -31.04M -28.55M -25.87M -48.36M -3.29B -49.27M -341M -137M -1.73B -130M -127M -5.46B
Net Debt	-5.77M -5.17M -4.76M -4.31M -8.05M -548M -8.21M -56.71M -22.77M -288M -21.66M -21.2M -909M	-17.81M -15.95M -14.67M -13.3M -24.85M -1.69B -25.32M -175M -70.25M -890M -66.85M -65.43M -2.81B